Treatment of obesity and type 2 diabetes with insulin-sensitizers such as TZDs has become a major challenge in clinical practice because of their side effects that include weight gain, cardiovascular complications, and increased risk of fractures [43]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.